Once viewed as a potential blockbuster destined to face off against Pfizer Inc.’s Prevnar 13, Genocea Biosciences Inc.’s pneumococcus vaccine, GEN-004, fizzled in top-line data from a phase IIa trial, performing better than placebo but not well enough to hit statistical significance. Read More
The 2015 BIO Investor Forum opens this morning at the Parc 55 San Francisco – a new venue that boasts “breathtaking views of Union Square, Twin Peaks and the Bay from every room and suite,” according to the Biotechnology Industry Organization (BIO). Read More
The biosimilars patent dance is twirling toward the Supreme Court, but the justices are likely to sit out Amgen Inc. v. Sandoz Inc. – or ask the solicitor general to cut in first. Read More
DUBLIN – Shire plc is betting that the outcome of a phase III trial of its dry eye treatment lifitegrast will be enough to get the drug over the line, following a complete response letter (CRL) issued by the FDA. Read More
HONG KONG – A new Chinese study showing that enhancement of the natural generation of new neurons using a biodegradable material that allows the gradual release of a neurotrophic agent could represent a novel strategy for treating spinal cord injuries (SCI). Clinical trials of the approach may be imminent. Read More
RIO DE JANEIRO, Brazil – A series of regulatory challenges across Latin America are hindering the development of biotech projects in a region many see as being fertile with potential. Read More
SHANGHAI – Clinical-stage immuno-oncology company, Beigene Co. Ltd., of Beijing, has announced its intention to raise $100 million on Nasdaq. Read More
HONG KONG – Another China-based company has filed for a $100 million IPO on Nasdaq, testing what has been a friendly environment for biotech. Hutchison China Meditech Ltd. hasn’t decided on the timeline of the listing, nor the number and price of shares. Read More
Delmar Pharmaceuticals Inc., of Vancouver, British Columbia, presented preclinical data at the American Association for Cancer Research Advances in Ovarian Cancer Research: Exploiting Vulnerabilities Conference in Orlando, Fla., demonstrating the potential of its lead product candidate, VAL-083, (dianhydrogalactitol) as a treatment for ovarian cancer. Read More
Naia Ltd., of Richmond, Calif., said it raised $5.3 million in a series A financing led by existing investor and strategic partner, Pharco Pharmaceuticals, of Alexandria, Egypt. Read More
strong>Cerulean Pharma Inc., of Cambridge, Mass., said the first patient has been dosed in a trial exploring a dose-intensive schedule for its lead nanoparticle-drug conjugate, CRLX101, in patients with advanced solid tumor malignancies. Read More
